Vita Life Sciences (ASX:VLS) said it expects full-year pre-tax profit between AU$13.2 million to AU$13.7 million, compared to 2024 pre-tax profit of AU$12.6 million, according to a Friday Australian bourse filing.
The company expects fiscal year sales between AU$91 million to AU$92 million, compared to sales of AU$79.5 million a year earlier.
The company said that export sales into China are expected to be slightly below initial expectations due to trade partner transition timing and softer channel performance.